Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
November 1, 2024
Tonix Pharmaceuticals presented positive data for TNX-801, their single-dose mpox vaccine candidate, at the World Vaccine Congress-Europe 2024. The vaccine showed strong tolerability in immunocompromised animals at doses 100 times higher than traditional vaccinia vaccines, without spreading to blood or tissues. TNX-801, based on synthesized horsepox, aligns with WHO's preferred criteria for mpox vaccines and has demonstrated protection against clade I monkeypox in animal studies. This development comes as clade I mpox spreads internationally, with cases reported in multiple countries. Tonix has partnered with Bilthoven Biologics for GMP manufacturing processes.
Tonix Pharmaceuticals has presented encouraging data for their novel mpox vaccine candidate TNX-801, demonstrating significant potential in addressing the evolving global mpox threat.
Key Features and Findings:
1. Vaccine Characteristics:
- Attenuated live-virus vaccine
- Based on synthesized horsepox
- Single-dose administration
- Minimally replicating
- High tolerability profile
2. Clinical Results:
- Safe in immunocompromised animals
- No spread to blood or tissues
- Effective at 100x traditional vaccine doses
- Provides single-dose immune protection
- Prevents clinical disease and lesions
- Reduces viral shedding
3. Strategic Advantages:
- Aligns with WHO's preferred criteria
- Potential for mucosal immunity
- May block forward transmission
- Ambient temperature stability
- Suitable for case-contact vaccination
4. Development Status:
- Presented at World Vaccine Congress-Europe 2024
- Manufacturing partnership with Bilthoven Biologics
- Part of Cyrus Poonawalla Group collaboration
- Targeting GMP manufacturing processes
5. Global Context:
- Addresses WHO's public health emergency
- Responds to international spread of clade I mpox
- Cases reported in multiple countries
- Addresses potential U.S. risk
The development of TNX-801 represents a significant advance in mpox prevention, offering potential advantages over existing vaccines in both efficacy and practical implementation.